Passage Bio, Inc. filed an amended and restated merger agreement with Remix Therapeutics, Inc., dated September 2, 2026, to implement a two-step merger structure while maintaining the original economic terms and aggregate equity values. The transaction involves a concurrent private placement financing of approximately $70.0 million, funded through pre-funded warrants purchased at $1.3860 each or Remix common stock at $1.3861 per share. Both companies' boards have approved and recommended the merger to their respective shareholders, with an outside closing date of December 24, 2026. Passage Bio, Inc. is a clinical-stage biotechnology company focused on developing gene therapies for rare diseases.

Passage Bio, Inc. entered into a merger agreement on June 24, 2026, with Remix Therapeutics, Inc., where Remix will become a wholly owned subsidiary of Passage Bio. Remix is valued at $226 million, while Passage Bio is valued at approximately $20 million. The deal includes a $100 million concurrent financing for Remix and the issuance of Contingent Value Rights (CVRs) to Passage Bio stockholders. Peter Smith, Ph.D., will serve as CEO of the combined company, and the board will consist of nine members designated by Remix. Additionally, Passage Bio terminated its development services agreement with Catalent Maryland, Inc. and its license agreement with the University of Pennsylvania for the PBFT02 program. Passage Bio is a biotechnology company focused on gene therapy.